Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Current Assets (2022 - 2025)

Zentalis Pharmaceuticals has reported Current Assets over the past 4 years, most recently at $253.2 million for Q4 2025.

  • Quarterly results put Current Assets at $253.2 million for Q4 2025, down 34.42% from a year ago — trailing twelve months through Dec 2025 was $253.2 million (down 34.42% YoY), and the annual figure for FY2025 was $253.2 million, down 34.42%.
  • Current Assets for Q4 2025 was $253.2 million at Zentalis Pharmaceuticals, down from $288.3 million in the prior quarter.
  • Over the last five years, Current Assets for ZNTL hit a ceiling of $563.9 million in Q2 2023 and a floor of $253.2 million in Q4 2025.
  • Median Current Assets over the past 4 years was $422.1 million (2022), compared with a mean of $411.2 million.
  • Biggest five-year swings in Current Assets: skyrocketed 36.16% in 2023 and later crashed 34.42% in 2025.
  • Zentalis Pharmaceuticals' Current Assets stood at $451.9 million in 2022, then grew by 9.91% to $496.7 million in 2023, then fell by 22.28% to $386.1 million in 2024, then plummeted by 34.42% to $253.2 million in 2025.
  • The last three reported values for Current Assets were $253.2 million (Q4 2025), $288.3 million (Q3 2025), and $311.6 million (Q2 2025) per Business Quant data.